New Jersey Medicaid Trust Attorney Christine Matus Explains Qualified Income Trusts

Navigating the strict financial requirements of Medicaid in New Jersey can be a significant barrier for many families seeking long-term care. New Jersey Medicaid trust attorney Christine Matus (https://matuslaw.com/understanding-qualified-income-trusts-in-new-jersey/) provides essential insights into how Qualified Income Trusts (QITs) serve as a crucial financial tool for individuals who exceed Medicaid income limits. Without compromising access to care or exhausting savings, these trusts offer a way to meet eligibility criteria while maintaining financial security.

New Jersey Medicaid trust attorney Christine Matus emphasizes that the state’s income limits are particularly challenging. In 2025, a single applicant’s monthly income must be below $2,901, while asset limits are capped at $4,000. For many, especially those relying on fixed incomes such as pensions or Social Security, even a slight overage can jeopardize their access to Medicaid. Christine Matus outlines how QITs allow excess income to be lawfully diverted, making it exempt from Medicaid’s calculations and enabling applicants to qualify for benefits they might otherwise be denied.

Christine Matus, an experienced New Jersey Medicaid trust attorney, details how a QIT operates. The trust must be irrevocable, meaning once it is established, it cannot be changed. It must be managed by a trustee who is not the Medicaid applicant—usually a family member or professional—and income over the Medicaid threshold must be deposited into a separate trust account each month. This income can then be used only for specific Medicaid-approved expenses, such as the applicant’s share of long-term care costs, personal needs allowance, or spousal income support. Misuse of the funds can result in disqualification from Medicaid, making trustee responsibilities especially critical.

“Redirecting excess income into the QIT and using it exclusively for allowable expenses helps applicants reduce their countable income and meet Medicaid’s requirements,” says Christine Matus. This approach becomes even more relevant for families navigating sudden care needs, such as a parent requiring immediate nursing home placement or individuals whose incomes fluctuate just above eligibility thresholds.

The process of establishing a QIT in New Jersey involves drafting a compliant trust document, selecting a trustee, and opening a bank account specifically for the trust. Christine Matus advises that the trust document must include specific language required under New Jersey Medicaid rules, and the timely monthly deposit of income into the account is non-negotiable. Failing to deposit the full amount of excess income, or missing a deposit entirely, can lead to delays or denial of Medicaid benefits.

Trustees also carry the responsibility of managing the funds in strict accordance with state guidelines. Funds cannot be used for general debts or unauthorized purchases, and meticulous records must be maintained to document every transaction. Christine Matus points out that oversight in any of these areas could threaten Medicaid eligibility and place unnecessary financial strain on families.

For seniors and caregivers in New Jersey, QITs serve a vital role. With nursing home care often exceeding $10,000 a month, the financial pressure can be immense. Christine Matus notes that many families are caught in a gap—earning too much to qualify for Medicaid, but not nearly enough to cover care costs independently. In such cases, QITs offer a reliable solution to gain access to vital long-term care services while protecting income and assets.

There are several situations where a QIT becomes especially important. These include reacting to unexpected long-term care needs, adjusting to income changes like cost-of-living increases, or managing finances within married couples where only one spouse requires Medicaid. Christine Matus emphasizes the importance of early planning and tailored legal strategies to avoid Medicaid eligibility pitfalls.

The Matus Law Group offers assistance for families looking to establish a Qualified Income Trust in New Jersey. Christine Matus works closely with clients to assess their financial circumstances, draft valid trust documents, guide trustee selection, and support families through every step of the Medicaid planning process.

Mistakes in establishing or managing a QIT can be costly. Christine Matus identifies common missteps such as failing to deposit income on time, using funds for ineligible expenses, choosing an unreliable trustee, or ignoring New Jersey-specific compliance rules. Avoiding these issues requires not just attention to detail, but a solid understanding of the legal framework behind Medicaid eligibility and trust administration.

A Qualified Income Trust is often the difference between receiving essential care and being left without options. Christine Matus and The Matus Law Group are dedicated to helping families create a plan that fits their unique situation, offering the clarity and legal support needed to move forward with confidence.

Families struggling with Medicaid eligibility in New Jersey due to income limitations can benefit significantly from a properly structured QIT. Christine Matus encourages individuals to take proactive steps to protect their financial health while accessing the care they need. With the right legal guidance, it is possible to secure Medicaid benefits without sacrificing stability or peace of mind.

About Matus Law Group:

The Matus Law Group, led by Christine Matus, provides legal support in New Jersey for Medicaid planning, estate law, and related services. The firm focuses on helping families navigate the legal and financial challenges associated with long-term care and asset protection.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=gS6_bQf-ro4

GMB: https://www.google.com/maps?cid=6876392708092026946

Email and website

Email: admin@matuslaw.com

Website: https://matuslaw.com/

Media Contact
Company Name: Matus Law Group
Contact Person: Christine Matus
Email: Send Email
Phone: (732) 281-0060
Address:81 E Water St #2C
City: Toms River
State: New Jersey 08753
Country: United States
Website: https://matuslaw.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Jersey Medicaid Trust Attorney Christine Matus Explains Qualified Income Trusts

Mosaic Media Films: Leading the Way in Video Production Services in Austin, TX

“na”
Mosaic Media Films is a top-tier video production company in Austin, offering a wide range of services including corporate videos, commercials, documentaries, and branded content. With years of experience and a reputation for quality, they specialize in creating visually captivating and engaging videos tailored to meet client needs. Their team utilizes state-of-the-art equipment and works closely with clients to bring their visions to life, ensuring exceptional results.

Austin, TX – Regarding professional video production, Mosaic Media Films – Austin Video Production Company stands out as a leader in the industry. Known for delivering top-quality content and creative storytelling, the company quickly becomes the go-to provider for businesses, brands, and individuals looking for expert video production services in Austin.

With years of experience in the field, Mosaic Media Films specializes in crafting high-quality videos that tell engaging stories and drive results. From corporate promotional videos to commercials, events, and more, their team of skilled filmmakers, directors, and producers offers a full spectrum of video production services. The company is dedicated to helping clients effectively communicate their messages with polished, visually captivating content.

“We believe that video is one of the most powerful ways to connect with audiences and create lasting impressions,” said a spokesperson for Mosaic Media Films. “Our team is passionate about turning ideas into compelling visuals that align with our clients’ goals and resonate with their target audiences.”

Whether a small-scale project or a large-scale production, Mosaic Media Films provides tailored services to meet each client’s unique needs. Their expertise spans various types of video production, including promotional videos, documentaries, event coverage, branded content, and more.

As a leading video production company, Mosaic Media Films utilizes state-of-the-art equipment and cutting-edge technology to ensure high-quality video output. From the initial concept development to post-production editing, the team takes pride in every aspect of the production process, ensuring that each video exceeds client expectations. With a reputation for excellence and attention to detail, Mosaic Media Films has established itself as one of the best video production companies in the Austin area.

Video Production Services Tailored to Your Needs

One of the reasons why clients keep returning to Mosaic Media Films is their ability to create custom-tailored video production services that meet each client’s specific objectives. The team works closely with clients from the beginning stages to understand their vision, messaging, and target audience. This collaborative process ensures that the final product is aligned with the client’s brand and marketing goals.

The company’s commitment to quality and customer satisfaction has earned it a solid reputation in Austin. With a focus on clear communication, creativity, and technical expertise, Mosaic Media Films ensures that clients receive the best possible service from start to finish.

Video Production for a Variety of Industries

Mosaic Media Films has a diverse portfolio, providing video production services for various industries, including:

Corporate Video Production: From internal training videos to corporate promotional materials, Mosaic Media Films helps businesses convey their message clearly and professionally.

Commercials and Advertising: The team creates high-impact commercials that attract potential customers in a competitive market.

Event Coverage and Documentaries: Whether it’s a corporate event, wedding, or special celebration, Mosaic Media Films offers high-quality event video coverage, capturing every critical moment with precision and care.

Branded Content: For businesses looking to connect with their audience on a deeper level, branded content production allows for storytelling that resonates with viewers while promoting a company’s values.

Why Choose Mosaic Media Films?

There are many video production companies in Austin, but Mosaic Media Films stands out for its commitment to excellence, creativity, and customer satisfaction. Here are a few reasons why clients choose them for their video production needs:

High-Quality Equipment: They use the latest video production technology, ensuring crisp visuals and superior sound quality.

Creative Expertise: The team is skilled in all aspects of filmmaking, from concept development to editing and post-production.

Personalized Approach: Mosaic Media Films takes the time to understand each client’s needs, ensuring that the final product aligns with their vision and objectives.

Experience and Reputation: With years of experience and a strong reputation in the Austin area, Mosaic Media Films has worked with many clients, from small startups to large corporations.

For businesses, brands, or individuals looking for top-notch video production services, Mosaic Media Films is the trusted partner in Austin. To learn more about their services or to request a consultation, visit Mosaic Media Films – Austin Video Production Company today.

Media Contact
Company Name: Mosaic Media Films – Austin Video Production Company
Contact Person: Mark Wonderlin
Email: Send Email
Phone: (512) 607-5533
Address:1505 W 6th Street Suite #AVP-301
City: Austin
State: TX
Country: United States
Website: https://mosaicmediafilms.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mosaic Media Films: Leading the Way in Video Production Services in Austin, TX

Empowering China, Global Connections: Interview with Jiang Xiaozhou, Deputy General Manager of TME China

Summary

Located in the core area of Shekou Commercial Circle, Nanshan District, Shenzhen, Water Bay 1979 is an internationally renowned art and cultural complex. In this issue, Kinghelm visits the Shenzhen Free Trade Center (Water Bay 1979) to interview Jiang Xiaozhou, Deputy General Manager of Transfer Multisort Elektronik (TME) China, a leading European distributor of electronic components. We explore how this global multinational corporation empowers China and connects the world!

image.png

Jiang Xiaozhou’s journey with TME began in 2018. Due to fluctuations in the capacitor and resistor supply chain, an increasing number of Chinese clients turned to TME’s website for procurement. TME established its China subsidiary in Shenzhen in 2017, which officially commenced operations in 2018, primarily providing sales support and services to Chinese customers. Reflecting on the past eight years, she mentioned that both she and the company had been “feeling their way forward” in the Chinese market. With TME’s continued expansion in China, the subsidiary’s team has now grown to 11 members. When asked how these 11 individuals effectively serve the Chinese market, Jiang Xiaozhou explained: “Every member of TME China is a pioneer in market development. The Poland headquarters ensures operational and logistical support, including warehousing, procurement, factory production, and event coordination. Under the leadership of General Manager Anna, we have made significant progress in enhancing customer loyalty and brand influence. Notably, Anna, the only expatriate in TME China, has contributed immensely to the company’s market expansion. Having studied, lived, and worked in China for many years, she not only speaks fluent Mandarin but also deeply understands Chinese culture, which fosters seamless communication with local employees and clients.”

image.png

TME China General Manager Anna (center) and Deputy General Manager Jiang Xiaozhou (second from right)

Jiang Xiaozhou introduced that Transfer Multisort Elektronik (TME), founded in 1989, is a global leader in the distribution of electronic components, workshop equipment, and industrial automation products. Headquartered in Poland, TME operates 12 subsidiaries worldwide with over 1,500 employees, serving 220,000 clients across 150+ countries. It offers more than 1 million product models from 1,300 renowned brands, covering semiconductors, IoT and embedded systems, optoelectronics, connectors, fuses, switches, relays, transformers, power supplies, cables, robotics, and more. These products are widely used in renewable energy, photovoltaics, wind power, logistics, and other sectors. All products are sourced directly from original manufacturers or authorized distributors. TME provides a one-stop professional procurement platform for global clients. Moving forward, TME looks forward to collaborating with outstanding Chinese companies like Kinghelm and Slkor to expand its international reach and support their brands in serving global customers

.image.png

TME China Subsidiary in Shenzhen

TME emphasizes collaboration. When discussing key partners in the electronics industry, Jiang Xiaozhou mentioned: “Mr. Song Shiqiang, General Manager of Kinghelm and Slkor, is a respected veteran in the semiconductor field. I met him at an event in Huaqiangbei and later deepened our connection through the ‘Sichuan-Chongqing Semiconductor Association Annual Meeting’ and the ‘TME 2024 Optimization and Innovation Symposium.’ These events showcased the warmth, optimism, and camaraderie of people from Sichuan and Chongqing, leaving a profound impression on me.”

image.png

Deputy General Manager Jiang Xiaozhou Participating in a Panel Discussion

Multiculturalism and inclusivity drive TME’s global reach. When asked about future plans, Jiang Xiaozhou highlighted that TME’s modern logistics center in Poland dispatches over 5,000 packages daily to 150+ countries. This year, TME China plans to establish a local warehouse, adopting a “global vision with localized operations” to better serve Chinese industrial clients and create greater value.

image.png

Jiang Xiaozhou (right) with Kinghelm and Slkor Representatives Song Shiqiang and He Junju

About Kinghelm

Kinghelm is a leading provider of high-quality electronic components, including RoHS-compliant antennas, wires, plug-ins, switches, and connectors. With over 17 years of experience, the company serves industries including automotive, telecommunications, industrial automation, medical devices, and consumer electronics. Kinghelm is known for its durable, reliable components that meet international standards and are used in applications ranging from renewable energy to IoT devices.

Media Contact
Company Name: Shenzhen Kinghelm Electronics Co., Ltd.
Contact Person: Support
Email: Send Email
Phone: +86 0755-83975897
Address:2010, Block A, Bairuida Building Vanke City Community Bantian Avenue, Longgang District
City: Shenzhen
Country: China
Website: www.kinghelm.net

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Empowering China, Global Connections: Interview with Jiang Xiaozhou, Deputy General Manager of TME China

Wound Closure Devices Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

DelveInsight’s Wound Closure Devices Market Insights Report provides the current and forecast market analysis, individual leading Wound Closure Devices Companies market shares, challenges, Wound Closure Devices Market Drivers, barriers, trends, and key market Wound Closure Devices Companies in the market.

To read more about the latest highlights related to the Wound Closure Devices Market, get a snapshot of the key highlights entailed in the Market Report @ Wound Closure Devices Market Size

Key Takeaways from the Wound Closure Devices Market Report

  • In February 2025, Northwestern University announced a study is to evaluate the efficacy of the Prevena Plus 125 therapy Unit (KCI USA, Inc.) in preventing surgical site infections and other wound complications in patients undergoing spine surgery compared to conventional wound dressing. Furthermore, the investigators want to illustrate which patients benefit most significantly from Prevena usage as spine surgery sees a range of potential candidates, and not all may experience equivalent recovery from spine surgery with Prevena intervention.
  • The Global Wound Closure Devices Market was valued at USD 14.82 billion in 2023, growing at a CAGR of 7.40% during the forecast period from 2024 to 2030, to reach USD 22.64 billion by 2030.
  • The leading Wound Closure Devices Companies such as Medtronic, 3M, Johnson & Johnson, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Inc., Healthium Medtech, Meril Life Sciences Pvt. Ltd., Futura Surgicare Pvt Ltd. Advanced Medical Solutions Group plc, Microcure (Suzhou) Medical Technology Co., Ltd., CooperSurgical Inc, Adhezion Biomedical, CENTENIAL SURGICAL SUTURE LTD, Cardinal Health, Dukal LLC, ORION SUTURES INDIA PVT LTD, Lotus Surgicals, and others.

To know more about why North America is leading the market growth in the Wound Closure Devices Market, get a snapshot @ Wound Closure Devices Market Outlook

Wound Closure Devices Market Dynamics

According to the latest data provided by the Diabetes Feet Australia (DFA) (2022), in Australia, 300,000 individuals are at risk of developing diabetic foot disease (DFD) per 100,000 population, with 50,000 already living with the condition. Of these, 12,500 people have undergone diabetes-related amputations, and 1,000 are currently hospitalized due to DFD. Additionally, as per the recent data and stats provided by IDF Atlas Report (2022), in African countries, the rates of diabetic foot ulcers (DFU) range from 10.0% to 30.0%, while the prevalence of lower limb amputations (LLA) varies between 3.0% and 35.0%. Diabetic foot ulcers are chronic wounds that often require specialized treatment and advanced wound closure solutions. As the prevalence of these ulcers rises, there is a growing demand for products that can effectively manage and close these wounds.

Wound Closure Devices Market Segmentation

Wound Closure Devices by Product Type (Sealants & Adhesives, Staplers, Sutures [Absorbable and Non-Absorbable], Hemostats, and Others), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the product type segment of wound closure devices market the sutures are expected to hold a significant share in 2023. Sutures play a significant role in boosting the overall market for wound closure devices due to their widespread use, versatility, and continuous innovation. Sutures are used in a variety of surgical procedures, from minor outpatient surgeries to major operations.

Get a sneak peek at the Wound Closure Devices Market Dynamics @ Wound Closure Devices Market Dynamics Analysis

Wound Closure Devices Companies

Medtronic, 3M, Johnson & Johnson, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Inc., Healthium Medtech, Meril Life Sciences Pvt. Ltd., Futura Surgicare Pvt Ltd. Advanced Medical Solutions Group plc, Microcure (Suzhou) Medical Technology Co., Ltd., CooperSurgical Inc, Adhezion Biomedical, CENTENIAL SURGICAL SUTURE LTD, Cardinal Health, Dukal LLC, ORION SUTURES INDIA PVT LTD, Lotus Surgicals, and others.

Wound Closure Devices Market Drivers

The major factors driving the demand for wound closure devices are the rising cases of chronic wounds, increasing traumatic injuries, recent product approvals, and increasing manufacturers’ initiative to develop technologically advanced products.

Which MedTech key players in the Wound Closure Devices Market are set to emerge as the trendsetter explore @ Wound Closure Devices Companies

Scope of the Wound Closure Devices Market Report

  • Coverage- Global
  • Wound Closure Devices Companies- Medtronic, 3M, Johnson & Johnson, B. Braun Melsungen AG, Baxter, Smith & Nephew, Stryker, Chemence Medical, Inc., Healthium Medtech, Meril Life Sciences Pvt. Ltd., Futura Surgicare Pvt Ltd. Advanced Medical Solutions Group plc, Microcure (Suzhou) Medical Technology Co., Ltd., CooperSurgical Inc, Adhezion Biomedical, CENTENIAL SURGICAL SUTURE LTD, Cardinal Health, Dukal LLC, ORION SUTURES INDIA PVT LTD, Lotus Surgicals, and others.
  • Wound Closure Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World

Interested in knowing the Wound Closure Devices Market by 2030? Click to get a snapshot of the Wound Closure Devices Market Trends

Table of Content

1. Wound Closure Devices Market Report Introduction

2. Wound Closure Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Wound Closure Devices Market Key Factors Analysis

6. Wound Closure Devices Market Porter’s Five Forces Analysis

7. Wound Closure Devices Market Assessment

8. Wound Closure Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wound-closure-device-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wound Closure Devices Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

Hormone Replacement Therapy Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

DelveInsight’s Hormone Replacement Therapy Market Insights Report provides the current and forecast market analysis, individual leading Hormone Replacement Therapy Companies market shares, challenges, Hormone Replacement Therapy Market Drivers, barriers, trends, and key market Hormone Replacement Therapy Companies in the market.

To read more about the latest highlights related to the Hormone Replacement Therapy Market, get a snapshot of the key highlights entailed in the Market Report @ Hormone Replacement Therapy Market Size

Key Takeaways from the Hormone Replacement Therapy Market Report

  • In April 2025, Vantive Health LLC announced a study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription.
  • In April 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.
  • The Hormone Replacement Therapy Market is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.
  • The leading Hormone Replacement Therapy Companies such as Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

To know more about why North America is leading the market growth in the Hormone Replacement Therapy Market, get a snapshot @ Hormone Replacement Therapy Market Outlook

Hormone Replacement Therapy Market Dynamics

The global average age for menopause onset in women is around 50 years. Women’s estrogen and progesterone production levels decrease significantly after the age of 50. The pituitary gland compensates for the decrease in estrogen and progesterone production by increasing the production of follicle-stimulating hormone (FSH). This manifests physically in women as post-menopausal symptoms such as flushing and others. According to data published in 2022 by the World Health Organization (WHO), it was stated that, in 2021, women aged 50 and over accounted for 26% of all women and girls globally. The increasing burden of women aged 50 across the globe will ultimately increase the overall menopausal load, thereby increasing the demand for hormonal replacement therapy used in the management of menopausal issues such as flushing of the skin, perspiration, and palpitations, among others.

Hormone Replacement Therapy Market Segment Analysis

Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others), Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), Route of Administration (Oral, Parenteral, and Transdermal), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Get a sneak peek at the Hormone Replacement Therapy Market Dynamics @ Hormone Replacement Therapy Market Dynamics Analysis

Hormone Replacement Therapy Companies

Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

Hormone Replacement Therapy Market Drivers

The hormone replacement therapy (HRT) market is experiencing significant growth, owing to the increasing prevalence of hormonal and targeted diseases like menopause and osteoporosis, along with an expanding geriatric population, which is driving the demand for hormone replacement therapy (HRT). Rising awareness about menopause management and interest in regenerative medicines, including anti-aging and reproductive cycle therapies, the surge in drug approvals, product launches, and the presence of key market players highlight the dynamic nature of the HRT market, which is projected to grow substantially from 2024 to 2030.

Which MedTech key players in the Hormone Replacement Therapy Market are set to emerge as the trendsetter explore @ Hormone Replacement Therapy Companies

Scope of the Hormone Replacement Therapy Market Report

  • Coverage- Global
  • Hormone Replacement Therapy Companies- Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
  • Hormone Replacement Therapy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World

Interested in knowing the Hormone Replacement Therapy Market by 2030? Click to get a snapshot of the Hormone Replacement Therapy Market Trends

Table of Content

1. Hormone Replacement Therapy Market Report Introduction

2. Hormone Replacement Therapy Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Hormone Replacement Therapy Market Key Factors Analysis

6. Hormone Replacement Therapy Market Porter’s Five Forces Analysis

7. Hormone Replacement Therapy Market Assessment

8. Hormone Replacement Therapy Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hormone-replacement-therapy-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hormone Replacement Therapy Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

Thyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 Million in 2022 and is projected to increase by 2034, estimates DelveInsight

DelveInsight’s “Thyroid Eye Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Thyroid Eye Disease Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Thyroid Eye Disease Therapeutics Market Outlook

Key Takeaways from the Thyroid Eye Disease Market Report

  • In April 2025, Tourmaline Bio Inc. announced a study of Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
  • In April 2025, Viridian Therapeutics Inc. conducted a study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
  • In April 2025, Amgen organized a study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
  • The total prevalent cases of thyroid eye disease in the United States were around 1,012,000 cases in 2022.
  • The US contributed to the largest prevalent population of thyroid eye disease, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
  • Among EU4 countries, Germany accounted for the largest number of thyroid eye disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
  • According to DelveInsight estimates, there were around 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease in Japan in 2022. These cases are projected to increase during the forecasted period.
  • In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from thyroid eye disease.
  • The diagnosis and treatment rate of thyroid eye disease is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of thyroid eye disease, thus leading to the increase in awareness among patients and clinicians.
  • The leading Thyroid Eye Disease Companies such as Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
  • Promising Thyroid Eye Disease Pipeline Therapies such as RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.

Stay ahead in the competitive landscape of the Thyroid Eye Disease Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Thyroid Eye Disease Treatment Market Size

Thyroid Eye Disease Epidemiology Segmentation in the 7MM

  • Thyroid Eye Disease Prevalent Cases
  • Thyroid Eye Disease Diagnosed Prevalent Cases
  • Thyroid Eye Disease Gender-specific Diagnosed Prevalent Cases
  • Thyroid Eye Disease Diagnosed Prevalent Cases
  • Moderate-to-severe Drug-treated Cases of Acute Thyroid Eye Disease Cases

Download the report to understand which factors are driving Thyroid Eye Disease epidemiology trends @ Thyroid Eye Disease Prevalence

Thyroid Eye Disease Marketed drugs

  • TEPEZZA (teprotumumab): Horizon Therapeutics

Insulin-like growth factor I receptor (IGF-IR) is implicated as a potential cause of thyroid eye disease, and overexpression of IGF-IR is found in orbital fibroblasts and lymphocytes. Features of thyroid eye disease include periorbital edema, proptosis, strabismus, and eyelid retraction, which can progress to vision-threatening complications, such as exposure keratopathy and compression neuropathy. Current management of this condition is not very effective and includes systemic steroids or radiation of the orbit, both of which are associated with significant adverse effects and complications.

Thyroid Eye Disease Emerging drugs

  • Batoclimab: Immunovant Sciences

Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection.

To learn more about Thyroid Eye Disease Treatment guidelines, visit @ Thyroid Eye Disease Market Drivers and Barriers

Thyroid Eye Disease Treatment Market Landscape

Thyroid eye disease treatment has evolved from nonspecific immunosuppression to targeted biological therapies. Current medical therapies target the active stage to decrease inflammation, minimize the worsening of functional ocular sequel, and in some cases, improve ocular signs, including proptosis and double vision. The mainstay of treatment for years has been steroids and orbital radiation (ORT). Several biologics have been assessed in recent years: rituximab, tocilizumab, and teprotumumab.

Thyroid Eye Disease Market Outlook

Thyroid Eye Disease treatment in the US is entering a new era with changing dynamics. To this date, only one drug has been approved by the US FDA to treat Thyroid Eye Disease: insulin-like growth factor-I receptor antagonist TEPEZZA. It is worth mentioning that the European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines 2021 recommends IV methylprednisolone in combination with oral mycophenolate sodium (or mofetil) as the first-line treatment for moderate-to-severe and acute thyroid eye disease, and in the more severe forms of moderate-to-severe and acute thyroid eye disease, including constant/inconstant diplopia, severe inflammatory signs and exophthalmos >25 mm, IV methyl-prednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy represents an additional valid first-line treatment.

Explore the dynamics of the Thyroid Eye Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Thyroid Eye Disease Ongoing Clinical Trials Analysis

Scope of the Thyroid Eye Disease Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Thyroid Eye Disease Companies- Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
  • Thyroid Eye Disease Pipeline Therapies- RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.
  • Thyroid Eye Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Thyroid Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Thyroid Eye Disease Market Access and Reimbursement

Table of Content

1 Key Insights

2 Thyroid Eye Disease Market Report Introduction

3 Thyroid Eye Disease Market Overview at a Glance

4 Executive Summary of Thyroid Eye Disease

5 Epidemiology and Market Methodology

6 Disease Background and Overview

7 Thyroid Eye Disease Epidemiology and Patient Population

8 Thyroid Eye Disease Patient Journey

9 Key Endpoints in Thyroid Eye Disease Clinical Trials

10 Thyroid Eye Disease Marketed Therapies

11 Thyroid Eye Disease Emerging Therapies

12 Thyroid Eye Disease: The 7MM Analysis

13 Thyroid Eye Disease Market Access and Reimbursement

14 Thyroid Eye Disease KOL Views

15 Thyroid Eye Disease SWOT Analysis

16 Thyroid Eye Disease Unmet Needs

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 Million in 2022 and is projected to increase by 2034, estimates DelveInsight

Idiopathic Pulmonary Fibrosis Treatment Market Size (7MM) was ~USD 3,300 million in 2023 and is projected to increase by 2034, estimates DelveInsight

DelveInsight’s report titled “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of burns, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Idiopathic Pulmonary Fibrosis Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Idiopathic Pulmonary Fibrosis Therapeutics Market Outlook

Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report

  • In April 2025, Tvardi Therapeutics announced a study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
  • In April 2025, GlaxoSmithKline announced a study will assess the safety and effectiveness of GSK3915393 in IPF participants. Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
  • In April 2025, Boehringer Ingelheim announced a study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
  • According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.
  • In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034).
  • Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.
  • In 2023, the prevalence of idiopathic pulmonary fibrosis in the 7MM was distributed as follows: mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC <50%) with 40,498 cases. This data underscores the significant number of patients in the moderate stage, indicating a critical need for effective management strategies.
  • In the epidemiological model of Idiopathic Pulmonary Fibrosis, cases in the 7MM for 2023 are categorized into age groups with 6,573 cases in the 18-39 years group, 24,492 in the 40-59 years group, 113,411 in the 60-79 years group, and 48,368 in those over 80 years, indicating a significant increase in prevalence with age.
  • In 2023, gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were higher in males, with approximately 120,718 cases, compared to females, who had around 73,152 cases, reflecting a higher prevalence in the male population.
  • The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
  • Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.

Stay ahead in the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Idiopathic Pulmonary Fibrosis Treatment Market Size

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM

  • Total Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases
  • Idiopathic Pulmonary Fibrosis Gender- specific Diagnosed Prevalent Cases
  • Idiopathic Pulmonary Fibrosis Age-specific Diagnosed Prevalent Cases
  • Idiopathic Pulmonary Fibrosis Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Prevalence

Idiopathic Pulmonary Fibrosis Marketed Drugs

  • OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

OFEV is a prescription drug for the treatment of IPF in adults. Nintedanib is the key ingredient and is a kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) a and ß, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3).

Idiopathic Pulmonary Fibrosis Emerging Drugs

  • BI 1015550: Boehringer Ingelheim

BI 1015550 is an investigational, oral phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects developed by Boehringer Ingelheim. BI 1015550 was studied as a monotherapy or in combination with background antifibrotic therapy to assess the effectiveness of slowing the rate of lung function decline in patients with Idiopathic Pulmonary Fibrosis. The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients.

To learn more about Idiopathic Pulmonary Fibrosis Treatment guidelines, visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

Idiopathic Pulmonary Fibrosis Drugs Market Insights

The main aim of treatment is to relieve the symptoms as much as possible and slow down its progression. There are two medicines that can help slow down the progression of idiopathic pulmonary fibrosis in people: ESBRIET (Pirfenidone) and OFEV (Nintedanib). Both drugs have shown to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies also shown decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and with pirfenidone rash, photosensitivity, and gastrointestinal discomfort. Gastrointestinal side effects are the most common reason for discontinuing both drugs.

Idiopathic Pulmonary Fibrosis Market Outlook

There are two antifibrotic agents approved for use in idiopathic pulmonary fibrosis. These are Pirfenidone and Nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.

Explore the dynamics of the Idiopathic Pulmonary Fibrosis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Idiopathic Pulmonary Fibrosis Ongoing Clinical Trials Analysis

Scope of the Idiopathic Pulmonary Fibrosis Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
  • Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, Pamrevlumab, PLN-74809, GSK3915393, BMS-986278, Taladegib, and others.
  • Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Idiopathic Pulmonary Fibrosis (IPF) Market Overview at a Glance

4 Idiopathic Pulmonary Fibrosis Epidemiology and Market Forecast Methodology

5 Key Events

6 Idiopathic Pulmonary Fibrosis Executive Summary

7 Idiopathic Pulmonary Fibrosis Market Disease Background and Overview

8 Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

9 Idiopathic Pulmonary Fibrosis Patient Journey

10 Idiopathic Pulmonary Fibrosis Marketed Drugs

11 Idiopathic Pulmonary Fibrosis Emerging Drugs

12 Idiopathic Pulmonary Fibrosis: Seven Major Market Analysis

13 Idiopathic Pulmonary Fibrosis KOL Views

14 Idiopathic Pulmonary Fibrosis SWOT Analysis

15 Idiopathic Pulmonary Fibrosis Unmet needs

16 Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

17 Appendix

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Treatment Market Size (7MM) was ~USD 3,300 million in 2023 and is projected to increase by 2034, estimates DelveInsight

Obsessive Compulsive Disorder Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Obsessive Compulsive Disorder Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive-Compulsive Disorder Therapeutics Market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Obsessive Compulsive Disorder Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Obsessive Compulsive Disorder Drugs Market Outlook

Key Takeaways from the Obsessive Compulsive Disorder Market Report

  • In March 2025, Biohaven Pharmaceuticals Inc. announced a study’s purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD).
  • In March 2025, Yale University announced a study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12.
  • Among the 7MM, the United States had the largest Obsessive-Compulsive Disorder Drugs Market Share in 2023, which accounted for approximately 55% of the total 7MM market.
  • The Obsessive-Compulsive Disorder Treatment Market Size in the US was ~USD 600 million in 2023.
  • In 2023, selective serotonin reuptake inhibitors (SSRIs) made approximately USD 290 million in revenue across the seven major markets, with antipsychotics ranking second, generating around USD 160 million.
  • The Obsessive-Compulsive Disorder Treatment Market Size in EU4 and the UK was ~USD 380 million in 2023.
  • The leading Obsessive Compulsive Disorder Companies such as Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.
  • Promising Obsessive Compulsive Disorder Pipeline Therapies such as Olanzapine, SXC-2023, Valbenazine Oral Capsule, Escitalopram, Seroquel XR, Sertraline and others.

Stay ahead in the competitive landscape of the Obsessive Compulsive Disorder Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Obsessive Compulsive Disorder Treatment Market Size

Obsessive Compulsive Disorder Epidemiology Segmentation in the 7MM

  • Total Obsessive-Compulsive Disorder Prevalent Cases
  • Total Obsessive-Compulsive Disorder Diagnosed Cases
  • Obsessive-Compulsive Disorder Gender specific Cases
  • Obsessive-Compulsive Disorder Severity-specific Cases
  • Obsessive-Compulsive Disorder Age-specific Cases

Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ Obsessive Compulsive Disorder Prevalence

Obsessive Compulsive Disorder Emerging Therapies

  • Troriluzole: Biohaven Pharmaceuticals

Troriluzole is a new chemical entity (“NCE”) and tripeptide prodrug of the active metabolite, riluzole. Troriluzole is optimized for improved bioavailability, pharmacokinetics, tolerability, and dosing compared to its active metabolite. Based on its Obsessive-Compulsive Disorder Mechanism of Action, preclinical data, and Obsessive-Compulsive Disorder Clinical Trials, troriluzole has the potential for therapeutic benefit in neurological and neuropsychiatric illnesses.

Obsessive Compulsive Disorder Market Outlook

OCD can be treated using pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or their combination. First-line treatments include cognitive-behavioral therapy and pharmacotherapy with the selective serotonin reuptake inhibitors (SSRIs). In this article we review evidence-based pharmacotherapies for OCD, as well as alternatives that may be considered in refractory patients. Other treatment modalities are reviewed in other articles in this issue. Unfortunately, even with optimal treatment, many patients continue to experience significant symptoms. Remission of moderate or severe OCD is uncommon, and long-term management is often necessary. The development of new, more effective treatment interventions represents an urgent clinical need.

To learn more about Obsessive Compulsive Disorder Treatment guidelines, visit @ Obsessive Compulsive Disorder Market Drivers and Barriers

Obsessive Compulsive Disorder Companies

Biohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.

Scope of the Obsessive Compulsive Disorder Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Obsessive Compulsive Disorder CompaniesBiohaven Pharmaceutical Holding Company Ltd., Alkermes plc, Intra-Cellular Therapies, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Mylan N.V., Cipla Limited, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Impel NeuroPharma, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson), Novartis International AG, Sun Pharmaceutical Industries Ltd., and Allergan plc (now part of AbbVie Inc.) and others.
  • Obsessive Compulsive Disorder Pipeline Therapies- Olanzapine, SXC-2023, Valbenazine Oral Capsule, Escitalopram, Seroquel XR, Sertraline and others.
  • Obsessive Compulsive Disorder Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Obsessive Compulsive Disorder Unmet Needs, KOL’s views, Analyst’s views, Obsessive Compulsive Disorder Market Access and Reimbursement

Explore the dynamics of the Obsessive Compulsive Disorder Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Obsessive Compulsive Disorder Ongoing Clinical Trials Analysis

Table of Contents

1. Key Insights

2. Obsessive Compulsive Disorder Market Report Introduction

3. Obsessive Compulsive Disorder Market Overview at a Glance

4. Obsessive Compulsive Disorder Executive Summary

5. Obsessive Compulsive Disorder Epidemiology and Market Methodology

6. Disease Background and Overview

7. Obsessive Compulsive Disorder Epidemiology and Patient Population

8. Obsessive Compulsive Disorder Patient Journey

9. OCD Marketed Therapies

10. Obsessive Compulsive Disorder Emerging Therapies

11. Obsessive Compulsive Disorder: The 7MM Market Analysis

12. KOL Views

13. SWOT Analysis

14. OCD Unmet needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obsessive Compulsive Disorder Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Pet Dietary Supplements Market Size, Share, Growth Drivers, Emerging Trends, Leading Players, Recent Developments, and Forecast – 2030

“MarketsandMarkets™”
Pet Dietary Supplements Market by Type (Dogs, Cats, and Other Pet Types), Supplement Form (Tablets & Capsules, Powders, Soft Chews, and Other Supplement Forms), Supplement Type, Function, Distribution Channel, and Region – Global Forecast to 2030

The pet dietary supplements market is estimated at USD 2.71 billion in 2025 and is projected to reach USD 4.11 billion by 2030, at a CAGR of 8.7% from 2025 to 2030. In addition to traditional products such as vitamins and minerals, there has been a rise in supplements that target specific pet health concerns, such as anxiety, stress relief, and obesity management. This has led to a surge in demand for more specialized formulations tailored to pets’ individual needs. Whether promoting better digestion, improving joint flexibility, or bolstering immune function, pet dietary supplements are becoming an essential part of the routine for many pet owners.

Pet Dietary Supplements Market

 

With the increased availability of these products through both traditional and online retail channels, pet owners have easier access to a broad range of dietary supplements. E-commerce platforms, in particular, have contributed to the market’s growth by allowing pet owners to compare products, read reviews, and have supplements delivered directly to their homes. This convenience has made it even more appealing for pet owners to incorporate supplements into their pets’ daily routines.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264349399

Why is the Pet Dietary Supplements Market Booming?

Several key factors are fueling the global expansion of the pet dietary supplements market:

  1. Humanization of Pets: Pet owners now approach pet care similarly to human healthcare. Products that were once only for humans—such as probiotics, multivitamins, CBD, and joint health supplements—are now being formulated specifically for dogs, cats, and even exotic animals.
  2. Rising Pet Ownership: Pet ownership increased dramatically during the COVID-19 pandemic, and that momentum has remained. More households with pets mean more demand for pet healthcare solutions.
  3. Preventative Healthcare Focus: Rather than waiting for illness, pet owners are investing in preventive care. Supplements for immunity, digestion, skin and coat health, and mobility are part of routine pet wellness strategies.
  4. Veterinarian Endorsements: Many veterinarians now recommend dietary supplements to support specific conditions or general wellness. This professional backing boosts consumer trust and drives growth.

 

Cats are estimated to account for a significant share among the pet types in the pet dietary supplements market.

Among various pet types, cats comprise a significant portion of the pet dietary supplement market. Pet owners are becoming more aware of the specialized nutritional needs of cats, which has driven demand for supplements aimed at improving feline health. Whether supplements support joint health, digestive well-being, or skin and coat conditions, cats benefit from tailored solutions that address common health concerns. As more pet owners turn to dietary supplements to help manage conditions in their cats, this segment continues to expand in both product variety and demand.

The omega-3 fatty acids segment has a significant share within the supplement type segment of the pet dietary supplements market

Omega-3 fatty acids are known for their ability to support the immune system, helping pets fight off infections and illnesses more effectively. As pets age, their immune systems can weaken, making them more susceptible to health issues. These fatty acids work to strengthen the immune response, promoting better overall health. Furthermore, these fatty acids are known for their potent anti-inflammatory properties, which can be particularly beneficial for pets suffering from conditions such as arthritis, joint pain, or skin irritations. By reducing inflammation, omega-3 supplements can improve mobility and comfort, especially in older pets.

Omega-3 fatty acids are also instrumental in improving skin and coat health. Regular supplementation helps maintain a glossy, healthy coat while reducing dry skin, shedding, and irritation. This has made omega-3 supplements a popular choice for pet owners who want to enhance the appearance and health of their pets’ fur. Many pets with skin sensitivities or allergies find relief from omega-3 supplementation, which helps to soothe inflammation and promote skin regeneration.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=264349399

Based on region, Europe is projected to grow at a significant rate in the pet dietary supplements market.

European pet owners are highly informed about the potential benefits of dietary supplements, often opting for premium, natural, and organic products to meet their pets’ specific needs. This trend aligns with the broader consumer movement toward cleaner, healthier, and more sustainable products across various sectors, and the pet care industry is no exception. Supplements that support joint health, digestive health, skin and coat condition, and cognitive function are seeing robust demand as European pet owners are increasingly proactive in addressing both standard and specialized health issues in their pets.

Europe has a rich market for both traditional and innovative pet supplement products, offering a wide range of solutions designed to cater to the diverse needs of pets. The availability of high-quality supplements, backed by stringent regulatory standards and product certifications, has bolstered consumer confidence in the safety and effectiveness of these products. European pet owners are willing to invest in premium formulations, such as omega-3s, vitamins, and herbal supplements, knowing that these products can support their pets’ longevity and quality of life.

Leading Pet Dietary Supplements Companies:

The report profiles key players such as Nestlé (Nestlé Purina Petcare Company) (Switzerland), Elanco (US), H&H Group (Hong Kong), SwedenCare (Sweden), Mars, Incorporated (US), Nutramax Laboratories (US), Virbac (France), General Mills Inc. (US), Zoetis Services LLC (US), Wellness Pet, LLC (US), NOW Foods (US), Vetoquinol (France), Affinity Petcare S.A (Spain), FoodScience (US), and Thorne Vet (US).

Recent Developments in the Pet Dietary Supplements Industry:

  • In February 2025, Elanco launched Pet Protect on February 20, 2025. This new line marks Elanco’s official entry into the pet dietary supplements category, leveraging its strong veterinary heritage and the trusted Advantage brand, which has been a staple in pet health for over 25 years. Pet Protect consists of a comprehensive range of veterinarian-formulated, science-backed supplements for dogs and cats. The portfolio addresses various wellness needs, including joint health, digestion, skincare, multivitamins, calming, and immune support.
  • In January 2025, Pooch & Mutt, one of the UK’s fastest-growing pet food brands, made a significant move in the pet wellness space by acquiring BIOME9, a pioneering company known for its science-backed, personalized gut health testing and supplement plans for dogs. This strategic acquisition reinforces Pooch & Mutt’s commitment to holistic, health-focused pet care.

 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/pet-dietary-supplements-market-264349399.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pet Dietary Supplements Market Size, Share, Growth Drivers, Emerging Trends, Leading Players, Recent Developments, and Forecast – 2030

Lightweight Aggregates Market: Industry Insights, Swot Analysis, Size, Share, And Key Growth Factors and Expert Review

“Browse 219 market data Tables and 53 Figures spread through 218 Pages and in-depth TOC on “Lightweight Aggregates Market””
The Lightweight Aggregates market is gaining traction due to growing demand in construction, especially for sustainable and energy-efficient buildings. With rising infrastructure projects and focus on reducing structural load, the market is set for steady growth across residential and commercial sectors.

The lightweight aggregates market size is projected to grow from USD 13.14 billion in 2025 and is projected to reach USD 15.52 billion by 2030, at a CAGR of 3.4%. This comprehensive study examines the lightweight aggregates market size, share, business trends, and key growth factors, providing valuable insights into future developments. In the construction industry, lightweight aggregates are used to make concrete and other building materials lighter. These aggregates consist of perlite, shale, expanded clay, and man-made aggregates like fly ash. As they improve fire resistance and lower structural load, they are utilized in concrete for bridges and high-rise structures applications. The use of lightweight aggregates is encouraged by government laws that support environmentally friendly building materials and the growing acceptance of green building certifications. This will propel the demand for lightweight aggregates market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8177489

Pumice accounted for the fourth largest share in the global lightweight aggregates market

Pumice has lightweight properties and has excellent performance in construction applications. Pumice is used in concrete production which helps in reducing the weight of infrastructure. It is resistant to chemicals, and moisture, thus it is a preferred choice for construction projects. Many countries are encouraging the use of eco-friendly building materials, this will propel the demand for pumice. As urbanization and infrastructure development are growing the demand for pumice will remain strong.

By end-use industry, infrastructure accounts for the second-largest share of the lightweight aggregates market

Infrastructure applications are growing due to large-scale construction projects such as bridges, roads, and tunnels. They help in reducing the weight of concrete structures. This weight reduction is important for bridges and highways as it minimizes stress on the foundations. Governments worldwide are investing in infrastructure modernization which will increase the demand for lightweight aggregates. As urbanization and smart city development are growing, the demand for lightweight aggregates in infrastructure projects will increase.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=8177489

Asia Pacific for the third largest share in the global lightweight aggregates market

Asia Pacific is the third-largest region because of rapid urbanization and infrastructure development. Countries like China, and India are investing in new roads and airports. The increasing demand for affordable housing and smart city projects in emerging economies is driving the use of lightweight aggregates in residential and commercial construction. Governments in the Asia Pacific are promoting eco-friendly building materials.

Lightweight Aggregates Companies

The major players in the lightweight aggregates market with a significant global presence are Arcosa, Inc. (US), Boral Industries Inc. (Australia), CEMEX S.A.B. de C.V. (Mexico), Leca International (Denmark), Stalite Lightweight Aggregate (US), among others. The market players have adopted various strategies such as expansions, agreements, and acquisitions, to strengthen their position in the lightweight aggregates market.

Arcosa Inc. (US) is a provider of infrastructure-related products and solutions, serving the construction, engineered structures, and transportation markets across North America. Incorporated in Delaware in 2018, Arcosa operates as an independent, publicly traded company listed on the New York Stock Exchange. The company operates through three main business segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment offers a range of products, including natural and recycled aggregates, specialty materials such as lightweight aggregates and plaster, and trench shields and shoring products. Its primary markets include infrastructure projects (such as roads, bridges, and other public works), residential and non-residential construction, agriculture, specialty building products, and underground construction. Arcosa Specialty Materials mines, mills, processes, and distributes lightweight aggregates, plaster products, gypsum, limestone minerals, and other downstream products for the food and building industries. Arcosa Lightweight is a part of the Arcosa family of companies and is the largest producer of rotary kiln expanded shale and clay lightweight aggregate in North America, with production facilities located in Alabama, Arkansas, California, Colorado, Louisiana, Indiana, Kentucky, and Texas.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=8177489

Boral Industries Inc. (Australia) is the largest vertically integrated construction materials company in Australia, with an extensive network of valued quarry and cement infrastructure, as well as bitumen, construction materials recycling, asphalt, and concrete batching operations. The company’s integrated network includes 360 operating sites and serves over 14,000 customers. Boral Australia produces a wide range of cementitious materials for various applications. Its upstream cement operations involve manufacturing clinker from its limestone, importing clinker for cement grinding, and processing fly ash and slag as supplementary cementitious materials

Cemex S.A.B. DE C.V. (Mexico) is aleading global provider of construction materials and solutions. The company offers a wide range of products, including cement, ready-mix concrete, aggregates, and urbanization solutions in growing markets worldwide. Cemex operates 60 cement and grinding plants, 232 aggregate sites, and 262 land distribution centers. Its business segments include cement, ready-mix concrete, urbanization solutions, and aggregates. Cemex delivers high-performance, innovative, and sustainable cement solutions, offering various types of cement such as Rugby Bagged Cement, Bulk Cement, and Fly Ash. Cemex has a strong global presence, with operations in the US, Mexico, South and Central America, the Caribbean, Europe, the Middle East, Asia, Africa, and other regions.

Leca International (Denmark) is a Saint-Gobain company specializing in the development, production, and marketing of Leca® products. Its primary product, Leca® Lightweight Aggregate (Leca® LWA), is a versatile, durable, and easy-to-use solution. Leca operates with a strong local presence in over 12 European countries. Production facilities are in Denmark, Sweden, Finland, Norway, Poland, and Portugal, while sales offices are established in the UK, Spain, Germany, Lithuania, Estonia, and Latvia.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lightweight-aggregates-market-8177489.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lightweight Aggregates Market: Industry Insights, Swot Analysis, Size, Share, And Key Growth Factors and Expert Review